Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Label-free quantitative proteomics of colon tissue from a Hirschsprung's disease patient carrying a NOS1 frameshift mutation

ABSTRACT: This study investigates the proteomic consequences of a frameshift mutation in the NOS1 (neuronal nitric oxide synthase) gene in the context of Hirschsprung's disease. Label-free quantitative (LFQ) mass spectrometry was performed on formalin-fixed paraffin-embedded (FFPE) colon tissue sections from one NOS1-mutant patient (3 technical replicates) and three control individuals. The study comprises two experimental arms: (1) total proteome profiling of all six samples, and (2) SDS-PAGE gel-band fractionation targeting proteins at ~55 kDa and ~160 kDa (migrating and narrow segments) for the three control samples. Raw data were acquired on a Thermo Fisher Orbitrap mass spectrometer and searched against the UniProt human reference proteome (UP000005640) using MaxQuant. A total of 2,193 proteins were quantified after QC filtering. Differential analysis (proDA, limma) identified 67 significantly altered proteins (adj.P<0.05, |log₂FC|>0.5; 25 upregulated, 42 downregulated) in the NOS1 mutant versus controls. NOS1 protein itself was not detected, consistent with mutation-induced protein instability or degradation. This dataset provides the first proteomic characterization of NOS1 loss-of-function in human colon tissue and complements parallel transcriptomic (RNA-seq, Iso-Seq) and immune profiling (flow cytometry) datasets from the same NOS1 mutation cohort.

ORGANISM(S): Homo Sapiens

SUBMITTER: Qian Jiang

PROVIDER: PXD080715 | iProX | Wed Jul 08 00:00:00 GMT+01:00 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Expression and 5' end mapping data for Mycobacterium tuberculosis with deletion of Rv2752c/rnj

Project description:We used three M. tuberculosis strains (WT H37Rv, an RV2752c deletion mutation, and the mutant complemented with an Rv2752c overexpression construct), extracted RNA from log phase cultures, and made RNAseq expression libraries as well as 5'-end-directed libraries.

2022-02-16 | GSE196357 | GEO

Deep Sequence Analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations

Project description:In this manuscript, we have used RNA-Sequencing experiment to obtain and integrate a variety of genomic features in order to identify signaling pathways that are associated to mutant KRAS lung tumors. 8 lung adenocarcinomas with mutant KRAS in lung tumors and 8 lung adenocarcarcinomas without KRAS mutation of which one sample is ran twice for QC purposes.

2012-06-07 | E-GEOD-34914 | biostudies-arrayexpress

Patterns of somatic uniparental disomy identify driver tumor suppressor genes in colorectal cancer [Illumina]

Project description:The aim of this study is to establish an integrative profiling of recurrent UPDs/UPPs, CNAs and genome-wide methylation status in sporadic CRC. Our results indicate that regions showing high frequencies of UPDs/UPPs mostly coincide with regions typically involved in genomic losses such as chromosome arms 1p, 5q, 8p, 14q, 17p, 18q, 20p, and 22q. Of these, chromosome arms 5q, 14q, 17p, and 20p preferentially showed UPDs/UPPs over genomic losses suggesting that tumor cells must maintain the disomic state of certain genes to favor cellular fitness. A meta-analysis using over 300 samples from The Cancer Genome Atlas confirmed our findings. In addition, the genes CSPG2, FLT4, SFRP1, DLK1, and GAS7 were frequently involved in regions of UPDs/UPPs and showed high levels of methylation revealing that UPDs/UPPs can result in the duplication of hypermethylated inactive genes. A total of 32 primary tumors from the colon and rectum were collected from the Hospital Clinic of Barcelona under the supervision of an experienced pathologist. DNA was extracted and bisulfited according to manufacturer's protocols. Matched patient DNA from normal mucosa was used as a reference for these experiments. This dataset includes methylation data for 29 colorectal cancers (only including those with good QC).

2015-09-02 | E-GEOD-64112 | biostudies-arrayexpress

Targeting β-catenin overcomes resistance to MEK inhibitor in PIK3CA mutant colon cancer

Project description:Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signaling pathway and attractive targets for cancer therapy. However, PIK3CA mutation, which commonly co-occurs with KRAS mutation, offered resistance to MEK inhibitor through activation of PI3K-AKT signaling. We identified a gene that cooperates with MEK inhibitors to forcefully treat PIK3CA mutant colon cancer cells. -catenin, a key molecule of the WNT pathway, emerged as a candidate by protein/Ab Chip array. MEK inhibitor treatment led to a decrease in -catenin in PIK3CA wild-type colon cancer cells but not in PIK3CA mutant colon cancer cells. Tumor regression was promoted by a combination of MEK inhibitor and NVP-TNS656, which targets the WNT pathway. Furthermore, combined inhibition of MEK and -catenin by NVP-TNS656 promoted tumor regression in colon cancer patient-derived xenograft (PDX) models expressing mutant PIK3CA. Taken together, we propose that inhibition of the WNT pathway, particularly -catenin, may bypass resistance to MEK inhibitor in human PIK3CA mutant colon cancer. Additionally, -catenin is a potential PD marker of MEK inhibitor resistance.

2015-08-13 | GSE71981 | GEO

Phenotypic heterogeneity analysis of APC-mutant colon cancer by proteomics and phosphoproteomics identifies RAI14 as a key prognostic determinant

Project description:Adenomatous polyposis coli (APC) is an important tumor suppressor and most directly related to the regulation of WNT/β-catenin signaling pathway. APC mutation has been identified as an early event in more than 80% of sporadic colorectal cancers (CRCs). However, obvious prognostic differences are observed in CRC patients with APC mutations. Although previous genomics has investigated the roles of concomitant gene mutations in determining the phenotypic heterogeneity of APC-mutant tumors, valuable prognostic determinants for APC-mutant CRC patients are still lacking. By using combined proteome and phosphoproteome, we classified the APC-mutant colon cancer patients and revealed the genomic, proteomic and phosphoproteomic heterogeneity in APC-mutant tumors. Of importance, we identified RAI14 as a key prognostic determinant for APC-mutant colon cancer patients, but not for APC-wildtype colon cancer patients. The heterogeneity and prognostic biomarkers in APC-mutant tumors were further confirmed in Clinical Proteomic Tumor Analysis Consortium (CPTAC) colon cancer cohort. In addition, we found that knockdown of RAI14 in cell lines led to reduced cell migration and changes in some epithelial-mesenchymal transition (EMT)-related markers. Mechanistically, knockdown of RAI14 was able to remodel the phosphoproteome associated with cell adhesion, which might promote F-action degradation and alter the expression of certain EMT markers. Collectively, this work describes the phenotypic heterogeneity of APC-mutant tumors and identifies the prognostic determinants for APC-mutant colon cancer patients. The prognostic utility of RAI14 in APC-mutant colon cancer will provide early warning and increase the chance of successful treatment.

2022-11-10 | PXD038081 |

Targeting β-catenin overcomes resistance to MEK inhibitor in PIK3CA mutant colon cancer

2015-08-13 | E-GEOD-71981 | biostudies-arrayexpress

Porphyromonas gingivalis: Control (Wild-type W83) vs. its htrA mutant

Project description:Transcriptional profiling of the wild-type and its htrA mutant. Identification of genes that are affected by the htrA mutation in P. gingivalis Keywords: Genetic modification Two-condition experiment, W83 vs. htrA mutant late-log growth phase. Biological replicates: 4 control, 4 mutant, independently grown. One replicate per array.

2010-05-26 | E-GEOD-10027 | biostudies-arrayexpress

LMN-1-DamID in N2 and set-25(n5021) met-2(n4256) mutant early C. elegans embryos

Project description:We asked if the perinuclear position of chromosome arms in C. elegans depends on the histone methyltransferases MET-2 and SET-25. To this end, we performed LMN-1-DamID in wild-type (N2) and mutant (set-25 met-2) strains. LMN-1-DamID signal on chromosome arms was significantly reduced in the mutant.

2012-09-04 | GSE37226 | GEO

human gut metagenome

Project description:QC sample

| PRJNA1057152 | ENA

Genome-wide analysis of PHABULOSA targets in Arabidopsis root meristem

Project description:We report the discovery of a root growth program in Arabidopsis that is independent of a functional quiescent center (QC). In this regulatory program, PHABULOSA (PHB), posttranscriptionally regulated by SHR and SCR, plays a central role. In phb shr and phb scr mutants, root meristem/growth activity recovers significantly. Interestingly, this recovery does not accompany the resurgence of QC cells. PHB regulates apical root growth in stele cells of the root meristem, located proximal to the QC. Our genome-wide investigation suggests that PHB exerts its influence on root growth by regulating auxin-cytokinin homeostasis. Apical root growth was restored when cytokinin levels were genetically reduced in the shr mutant. Conversely, when miRNA-resistant PHB was expressed in the root stele cells, apical root growth and meristem functions were significantly inhibited without blocking the QC identity. Taken together, our investigation reveals two mechanisms through which SHR regulates root growth and stem cell activities: one is to specify and maintain the QC and the other is to regulate the proximal meristem activity through PHB and cytokinin. In this regulation, QC seems to be more involved in maintaining the “growth signal” and thus ensure the indeterminate root growth.

2012-12-31 | GSE33015 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data